

20. (Cancelled) The method of claim 9 wherein said amount of (R,R '),(R,S ')-amphetamine sulfate or another pharmaceutically-acceptable salt thereof, substantially free of (S,R '),(S,S')-amphetamine is administered together with a pharmaceutically-acceptable carrier, diluent, excipient or additive.
21. (Cancelled) The method of claim 9 wherein said condition or disease is narcolepsy, attention deficit hyperactivity disorder (ADHD), depression, Parkinson's disease, cognitive dysfunction, or Alzheimer's disease, renal dysfunction, asthma, obesity, nicotine withdrawal, hypotension, apathy, potentiating activity of a conventional antidepressant, potentiating an opiate for pain control, or reduced energy associated with chemotherapy or radiation therapy.
22. (Cancelled) The method of claim 9 wherein said condition or disease is amenable to treatment 15 by preferential activation of mesolimbic-mediated behavior.

#### **REMARKS**

In the office action dated August 25, 2003, the Examiner stated that claims 1-8 were allowable. The Petitioners wish that such claims be allowed and have cancelled claims 9-22.

Sincerely,

A handwritten signature in cursive script that reads "Karen Guerrero". The signature is fluid and elegant, with the first name "Karen" and the last name "Guerrero" clearly distinguishable.

Karen Guerrero  
Reg. No. 37,071  
Vela Pharmaceuticals, Inc.  
609-771-8660 ext. 118